{
    "nct_id": "NCT04373785",
    "official_title": "A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients",
    "inclusion_criteria": "* Male or female subjects ≥ 18 years of age\n* Must be newly diagnosed with GBM\n* Primary treatment must consist of a chemoradiation therapy (CRT) regimen\n* Hemoglobin > 9 g/dL\n* White blood count 3,600 - 11,000/mm3\n* Absolute neutrophil count (ANC) ≥ 1,500/mm3\n* Absolute lymphocyte count (ALC) ≥ 1,000/mm3\n* Platelet count 100,000/mm3\n* BUN ≤ 1.5 times upper limit of normal\n* Creatinine clearance rate > 40 mL/min\n* ALT ≤ 3 times upper limit of normal\n* AST ≤ 3 times upper limit of normal\n* Alkaline phosphatase ≤ 3 times upper limit of normal\n* Total bilirubin ≤ 2.0 mg/dL\n* Karnofsky Performance Status ≥ 70\n* Must not be on any other alternative therapies\n* Not pregnant\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to meloxicam, famotidine, and/or caffeine or any of their derivatives or components\n* Known allergy to vitamin A, vitamin D3, and/or L-citrulline\n* Pregnant women\n* Breastfeeding women\n* Corticosteroid therapy that cannot be tapered down to a dose of 1 - 2 mg/day of dexamethasone or its equivalent\n* History of immunodeficiency diseases or autoimmune diseases\n* History of peptic ulcer disease or gastrointestinal perforation",
    "miscellaneous_criteria": ""
}